Innovating Works

AZIENDA OSPEDALIERA CITTA DELLA SALUTE E...

Desconocido
ThermoBreast: An innovative non-contact and harmless screening modality set to change the course of breast cancer... AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un HORIZON EUROPE: HORIZON-MISS-2021-CANCER-02 Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated more than 2....
2022-11-28 - 2026-12-31 | Financiado
EU-TOPIA-EAST: TOwards imProved screening for breast cervical and colorectal cancer in Eastern Europe Equitable... AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-SC1-BHC-2018-2020 Colorectal, breast and cervical cancer cause 155,000 deaths each year in middle income countries (MIC) in Eastern Europe, while there is goo...
2021-02-04 - 2026-04-30 | Financiado
RISCC: RISK BASED SCREENING FOR CERVICAL CANCER AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-SC1-BHC-2018-2020 Screening for cervical cancer is a globally recommended public health policy. Many risk factors are known, but so far only one-size-fits-all...
2019-12-06 - 2024-12-31 | Financiado
DECISION: DECOMPENSATED CIRRHOSIS IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-SC1-BHC-2018-2020 In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. developm...
2019-12-05 - 2025-09-30 | Financiado
DeepHealth: Deep Learning and HPC to Boost Biomedical Applications for Health AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-ICT-2018-20 Health scientific discovery and innovation are expected to quickly move forward under the so called fourth paradigm of science, which relies...
2018-12-05 - 2022-06-30 | Financiado
MyPeBS: International Randomized Study Comparing personalized Risk Stratified to Standard Breast Cancer Scr... AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-SC1-2016-2017 MyPeBS addresses the crucial and timely question of the future of breast cancer screening in Europe. Indeed current standard mammographic sc...
2017-12-05 - 2026-06-30 | Financiado
LIVERHOPE: SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-SC1-2016-2017 Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact...
2016-12-09 - 2023-02-28 | Financiado
RHAPSODY: Assessing risk and progression of prediabetes and type 2 diabetes to enable disease modification S... AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-JTI-IMI2-2015-03-two-stage The stated goal of RHAPSODY is to define a molecular taxonomy of type 2 diabetes mellitus (T2D) that will support patient segmentation, info...
2016-06-07 - 2021-09-30 | Financiado
EU-TOPIA: EU TOPIA TOWARDS IMPROVED SCREENING FOR BREAST CERVICAL AND COLORECTAL CANCER IN ALL OF EUROPE AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un H2020: H2020-PHC-2014-2015 Breast, colorectal and cervical cancer cause 250,000 deaths each year, representing 20% of EU-cancer mortality. Although important progress...
2015-04-13 - 2020-08-31 | Financiado
KidneyConnect: A Gateway to European Kidney Research Resources KidneyConnect AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un FP7: Diabetes, Cardiovascular and Chronic kidney (DCC) -diseases are relentlessly increasing globally, causing enormous human suffering, prematur...
Financiado
COHEAHR: Comparing health services interventions for the prevention of HPV related cancer AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un FP7: Important progress has been made in the field of HPV-disease prevention with the development and implementation of HPV vaccines and HPV DNA...
Financiado
PREHDICT: health economic modelling of PREvention strategies for Hpv related Diseases in European CounTries AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO participó en un FP7: The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and to predict the impac...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.